The role of CYP17A1 and CYP17A1 inhibition in prostate cancer chemotherapy is an emerging therapeutic strategy for prostate cancer that functions by suppressing androgen production, as androgen is required for tumor growth. This evidence concerns the gene CYP17A1 and prostate carcinoma.